Kornimate/medical-research-clean huggingface dataset:
the role of muscle in knee stability

Conditions: Anterior Cruciate Ligament Injuries

Summary: this project aims to compare the difference in muscle strength, muscle elasticity and muscle coordination of quadriceps and hamstring muscle and their association with knee biomechanics during single leg hop landing in patients with anterior cruciate ligament reconstruction.

in hong kong, over 3000 cases of anterior cruciate ligament reconstruction (aclr) are operated annually to restore knee stability. despite recovery of knee passive laxity and muscle strength, dynamic knee stability is often not restored. in additional to muscle strength, muscle elasticity and muscle coordination may also play an important role in knee stability. however, there is no evidence regarding the changes in muscle elasticity after aclr and its contribution to dynamic knee stability. this study is a cross-sectional study designed to compare the the difference in muscle strength, muscle elasticity and muscle coordination of quadriceps and hamstring muscle in 30 aclr patients and investigate its relationship with knee biomechanics during single leg hop landing. patient selection was base on medical records and subjective knee functional scores. patient enrollment and informed consent was conducted first. muscle strength was measured by isokinetic muscle testing(biodex) at two speeds. muscle elasticity was assessed by ultrasound shear wave elastography. muscle coordination evaluated by electromyography(emg) and knee biomechanics including kinematics and kinetics was measured by 3d motion analysis system(vicon) and all the assessments were done in cuhk-ort sports injury research laboratory in the prince of wales hospital, hong kong. all data was collected and analyzed by qualified personnel.

Eligibility criteria:
inclusion criteria: * (1) male aged 18-35 (2) with pre-injury activity level of more than 6 in tegner score (3) within their post-operative 6-18 months (4) without injury history for the contralateral limb exclusion criteria: * (1) with concomitant fracture, meniscus injury or chondral lesion (2) with preoperative radiographic signs of arthritis (3) with revision acl surgery (4) with injury history of the spine or hamstring strain during the past 6 months.

Keywords: muscle strength muscle elasticity muscle coordination knee stability
epidemiology of ulcerative colitis and crohn's disease in non jewish israel population

Conditions: Ulcerative Colitis; Crohn's Disease

Summary: the aim of the present study was to describe the incidence and prevalence of ibd in non jewish israel population

we are interest to collect the detail of gender, age, duration of the disease and therapy to obtain the information we wont to contact each physician by e-mail, phone , and fax .

Eligibility criteria:
inclusion criteria: * ulcertive colitis and crohn's disease patients exclusion criteria: * n/a

Keywords: prevalence incidence crohn's disease ulcerative colitis epidemiology
effects of blood flow restriction training on muscle strength and physical function for stroke-related sarcopenia

Conditions: Sarcopenia; Chronic Stroke Patients

Summary: effects of blood flow restriction walking on muscle strength and physical function in chronic stroke patients with sarcopenia: a randomized, sham-controlled trial primary objective: to evaluate the effects of bfr walking on muscle strength and physical function in chronic stroke patients with sarcopenia, compared to sham-bfr walking. secondary objective: (1) to explore the potential impact of bfr walking on muscle mass and vascular function in chronic stroke patients with sarcopenia. (2) to assess the influence of bfr walking on quality of life in chronic stroke patients with sarcopenia.


Eligibility criteria:
inclusion criteria: * diagnosed with chronic stroke (≥6 months post-stroke) * diagnosed with sarcopenia, based on awgs 2019 criteria exclusion criteria: * stroke occurred within the past 6 months * resting systolic blood pressure \> 200 mmhg * resting diastolic blood pressure \> 100 mmhg * presence of implanted electronic or metallic devices that interfere with blood flow restriction cuffs * contraindication to bioelectrical impedance analysis (e.g., pacemaker, icd)
the effect of the reflux band™ upper esophageal sphincter (ues) assist device on reflux for lung transplant recipients

Conditions: Lung Transplant; GERD

Summary: a prospective, open label, study designed to assess the affect of the reflux band® ues assist device (reflux band) on reflux in patients that have undergone lung transplantation.


Eligibility criteria:
inclusion criteria: * clinically stable lung transplant patients(single lung, double lung, or re-transplant) as defined by stable fev1 over the prior two visits * 13 abnormal ph impedence or esophagram or documented gastric reflux at pre-transplant evaluation * patient must be willing and able to provide informed consent * understands the clinical study requirements and is able to comply with follow-up schedule exclusion criteria: * currently being treated with another investigational medical device and/or drug * currently receiving treatment for sleep apnea with continuous positive airway pressure (cpap) * previous head or neck surgery / radiation * carotid artery disease, thyroid disease, or history of cerebral vascular disease * nasopharyngeal cancer * suspected esophageal cancer
comparison between right and left ventricular systolic dysfunction as a risk factors for aki in critical care patients

Conditions: Acute Kidney Injury (Nontraumatic)

Summary: the cardio renal syndrome generally focuses on left ventricular function, and the importance of the right ventricle as a determinant of renal function is described less frequently. although the risk of aki is similar for patients with isolated lvd and isolated rvd, the severity of aki and the associated risk of hospital mortality is highest among those with isolated rvd.

the right ventricle seems to affect renal function through different mechanisms, including venous congestion, tricuspid regurgitation, and potential inhibitory effect on left ventricular function the most important mechanism is venous congestion, a manifestation of sodium avidity and fluid expansion, as directly increasing renal venous pressure causes sodium retention, lowers urinary output, and decreases glomerular filtration and widely thought to explain aki venous pressure is directly associated with renal dysfunction, independently of ventricular function, and admission peripheral edema is associated with greater risk of aki. such awareness of a primary role of renal venous congestion reshapes our understanding of renal function as not simply a reflection of arterial perfusion, but rather a balance between arterial supply and venous drainage. .

Eligibility criteria:
inclusion criteria: * cardiac patient exclusion criteria: * esrd pt ckd cirrhotic patients aki due to post renal cause
fit and fecal calprotectin in patients with chronic lower gi symptoms

Conditions: Colorectal Cancer; Colorectal Adenoma; Colitis

Summary: chronic lower gastrointestinal (gi) symptoms, including lower abdominal pain, bowel habit change, bleeding per rectum, and abdominal bloating, are caused by functional gastrointestinal disorders (fgid) and organic intestinal disorders, including colorectal cancer and chronic colitis. the presence of alarming features, such as the age of onset older than 50 years, rectal bleeding, anemia, significant weight loss, and family history of colorectal cancer, indicates organic diseases, and colonoscopy should be required. however, using only alarming features may not be sufficiently accurate. for example, anemia or significant weight loss, which are highly specific for organic disorders, usually occur in late-stage diseases. conversely, the parameters with high sensitivity, such as the age of onset after 50 years, have a low specificity; colonoscopy in these patients may not be urgent. therefore, tests that can help discriminate organic from functional diseases are warranted. immunochemical fecal occult blood tests (ifobt) and fecal calprotectin (fc) are biomarkers that indicate organic lesions in the gastrointestinal tract and could help diagnose patients with lower gi symptoms more accurately.

this study was a single-center, prospective cohort study undertaken at siriraj hospital between march 2020 to november 2022. eligible participants were required to collect their stool samples one to two days before the bowel preparation. the stool was sent for fresh smear examination, quantitative fit (oc-sensor, eiken chemical, japan), and quantitative fecal calprotectin (elia calprotectin 2, phadia, sweden). blood samples were obtained on the day of the colonoscopy and were tested for complete blood count, albumin, and c-reactive protein (crp) levels. in addition, clinical information was obtained, including alarm features such as the age of onset older than 50 years, rectal bleeding, anemia, significant weight loss, and family history of colorectal cancer. colonoscopic findings and histopathological findings were used as the reference standard for diagnosis. we analyzed the sensitivity, specificity, positive predictive value (ppv), and negative predictive value (npv) for diagnosing significant ileocolonic lesions, including colorectal cancer, advanced adenoma, and colitis, of each diagnostic modality comparing to the reference standard.

Eligibility criteria:
inclusion criteria * age of at least 18 years * patients with at least one month of any lower gastrointestinal symptoms are as followings; lower abdominal pain, constipation, diarrhea, rectal bleeding, change in stool caliber, abdominal bloating, * patients who are scheduled for a colonoscopy exclusion criteria * incomplete colonoscopy * incomplete stool collection

Keywords: fecal immunochemical test calprotectin colorectal neoplasm colorectal cancer colitis
in.pact admiral drug-coated balloon vs. standard balloon angioplasty for the treatment of superficial femoral artery (sfa) and proximal popliteal artery (ppa)

Conditions: Femoral Artery Stenosis; Popliteal Artery Stenosis; Femoral Artery Occlusion; Popliteal Artery Occlusion

Summary: the purpose of the study is to demonstrate the safety and efficacy of the in.pact admiral drug-coated balloon (dcb) in comparison to any standard balloon for treatment of peripheral arterial disease (pad) in the superficial femoral artery and proximal popliteal artery.

the in.pact sfa trial enrolled in 2 phases: in.pact sfa i and in.pact sfa ii. the 150-patient in.pact sfa i phase is intended to support the second phase in.pact sfa ii ide trial with congruent design and protocol. aggregate data from the two phases is intended to provide statistical power for the 12-month primary safety and effectiveness endpoints.

Eligibility criteria:
inclusion criteria: * age: \> or equal to 18 years and \< or equal to 85 years * documented ischemia with rutherford classification 2, 3, or 4 * target lesion in the sfa and/or ppa * angiographic evidence that target lesion consists of a single de novo or non-stented restenotic lesion or is a combination lesion that meets the following criteria: 1. 70 - 99% occlusion by visual estimate with lesion length \> or equal to 4 cm and \< or equal to 18 cm 2. 100% occlusion by visual estimate with lesion length \< or equal to 10 cm 3. combination lesions must have a total lesion length of \> or equal to 4 cm and \< or equal to 18 cm with an occluded segment that is \< or equal to 10 cm (by visual estimate) * target vessel diameter \> or equal to 4 mm and \< or equal to 7 mm * angiographic evidence of adequate distal run-off to the ankle * able to walk without assistive devices exclusion criteria: * stroke or heart attack within 3 months prior to enrollment * enrolled in another investigational drug, device or biologic study * any surgical procedure or intervention performed within 30 days prior to or post index procedure * sfa or ppa disease in the opposite leg that requires treatment at the index procedure * failure to successfully cross the target lesion * angiographic evidence of severe calcification * target lesion requires treatment with alternative therapies such as stenting, laser, atherectomy, cryoplasty, brachytherapy, re-entry devices) * known allergies or sensitivity to heparin, aspirin, other anticoagulant/antiplatelet therapies, paclitaxel or contrast media that cannot be adequately pre-treated prior to index procedure * chronic kidney disease

Keywords: drug-coated angioplasty balloon drug coated angioplasty balloon peripheral artery disease experimental percutaneous transluminal angioplasty (pta)
study to assess the safety and effects of autologous adipose-derived stem cells in patients with frailty syndrome

Conditions: Frailty Syndrome

Summary: the intent of this clinical study is to answer the questions: 1. is the proposed treatment safe 2. is treatment effective in improving the health of patients with human frailty syndrome.

this will be an open-label, non-randomized multi-center patient sponsored study of autologous adipose-derived stem cells (asc) implantation after liposuction using an iv delivery system. ascs will be derived from the patient's adipose-derived tissue. liposuction using local anesthesia and syringe collection will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells. the cells will be delivered intravenously.

Eligibility criteria:
inclusion criteria: * males and females age \>55. * frailty syndrome defined by: bmd\ 17% fat, females\ 24% fat (lean body mass=total body mass- %body fat) * ability to participate in the short physical performance battery * up to date on all age and gender appropriate cancer screening per american cancer society exclusion criteria: * life expectancy \< 6 months due to concomitant illnesses. * exposure to any investigational drug or procedure within 1 month prior to study entry or enrolled in a concurrent study that may confound results of this study. * active infectious disease patients known to have tested positive for hiv, htlv, hbv, hcv, cmv (igm \> igg) and/or syphilis. will have an expert consulted as to patient eligibility based on the patient's infectious status * any illness which, in the investigator's judgment, will interfere with the patient's ability to comply with the protocol, compromise patient safety, or interfere with the interpretation of the study results * patients on chronic immunosuppressive transplant therapy * active clinical infection being treated by antibiotics within one week of enrollment. * known drug or alcohol dependence or any other factors which will interfere with the study conduct or interpretation of the results or who in the opinion of the investigator are not suitable to participate. * history of cancer (other than non-melanoma skin cancer or in-situ cervical cancer) in the last five years. * unwilling and/or not able to give written informed consent.
efficacy biomarkers of daoib for dementia

Conditions: Dementia

Summary: this open-label clinical trial will enroll patients with amci or mild ad, and they will be treated with daoib for 24 weeks. we will assess the patients before entering the study, 8 weeks, 16 weeks, and end point (24 weeks) of the study, and measure blood nmda and oxidative stress - related biomarkers every 8 weeks. we hypothesize that nmda and oxidative stress - related biomarkers can predict the efficacy of daoib for patients with amci or mild ad.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of alzheimer's disease or mild cognitive impairment * mmse between 10-26 * cdr 1 or 0.5 exclusion criteria: * hachinski ischemic score \> 4 * substance abuse/dependence * parkinson disease, epilepsy, dementia with psychotic features * major depressive disorder * major physical illnesses * severe visual or hearing impairment
rad 1802: pilot trial of five fraction stereotactic body radiotherapy for early stage breast cancer patients eligible for post-operative accelerated partial breast irradiation (apbi)

Conditions: Breast Cancer

Summary: this study offers 5 fractions of radiation treatment through partial breast irradiation in patients with early stage breast cancer after having a lumpectomy.

this study offers 5 fractions stereotactic body radiotherapy for early stage breast cancer after patient undergoes a lumpectomy. the study aims to determine the safety and feasibility of delivering only 5 doses of radiation treatment rather than the longer schedule of treatments that is currently considered standard of care for breast cancer patients. patients will be followed for 36 months (2 years) with follow-up appointments at 6, 12, 18, 24, and 36 months.

Eligibility criteria:
inclusion criteria: * pathologically proven invasive mammary carcinoma, invasive ductal carcinoma (idc) or ductal carcinoma in situ (dcis) of the breast. medullary, papillary, mucinous (colloid) and tubular histologies are allowed. * age\>50. * maximum pathologic tumor size \<2.0cm if invasive carcinoma or \< 2.5cm if pure dcis. * estrogen receptor (er) positive (\>10%). * must be eligible for breast conservation therapy and receive a lumpectomy with pathologic margins of at least 2mm. * must be clinically node negative by physical examination. sentinel node dissection is not required, but if undertaken, the patient must be pathologically node negative. * zubrod performance status 0-2. exclusion criteria: * multifocal or multicentric cancer. * reception of neoadjuvant chemotherapy. * pure invasive lobular histology. * inability to clearly delineate lumpectomy cavity on post lumpectomy planning scan. * measured maximum ptv of \>124cc. * lumpectomy cavity within 5mm of body contour.

Keywords: sbrt breast cancer early stage radiation therapy
explore the impacts of one session theta burst stimulation over cerebellum in adults with autism spectrum disorder

Conditions: Autism Spectrum Disorder

Summary: the investigator would like to investigate the impact of theta-burst stimulation over cerebellum in adults with autism spectrum disorder


Eligibility criteria:
inclusion criteria: * adults with autism spectrum disorder (≥18 years old), confirmed by autism diagnostic observation schedule. exclusion criteria: * previous or current severe neurological disorder such as epilepsy, visual or hearing impairment. * previous or current severe systemic disease such as cardiovascular disease, diabetes or infection. * previous or current severe brain injury * implementation of metal materials such as pacemaker or medication pump * previous or current severe psychiatric disorders such as schizophrenia, bipolar disorder or substance abuse * pregnancy * individuals with a significant brain abnormality such as intracranial space occupied lesions * history of brain surgery or nervous system infection, such as meningitis and encephalitis * concurrent use of medications which increased the risk of seizure attack * participate another clinical trial within one month * skin trauma on application site * individuals suffering from multiple sclerosis * individuals with a large ischemic scar * individuals suffering from sleep deprivation during rtms procedures * individuals with a heavy consumption of alcohol * current taking antiepileptic drugs * individuals with a migraine headache from increased intracranial pressure * unable to complete mri scan withdrawal criteria: * seizure attack during study period * autistic symptoms worsened obviously during study period * extreme agitation or irritability during study period * participants request * take antiepileptic drug during study period
high flow nasal cannula versus nasal intermittent positive pressure (nippv) in preterm infants

Conditions: Preterm Infant

Summary: the aim of this study is to compare the effectiveness of heated humidified high flow nasal cannula (hhhfnc) versus nasal intermittent positive pressure ventilation (nippv) in preventing intubation when used as primary respiratory support for respiratory distress syndrome (rds) or post extubation in preterm infants

patient population will include preterm infants born at 24 - 36+6 weeks of gestation who are candidates for non-invasive respiratory support post extubation or as primary respiratory support after birth. they will be will be randomized to 2 groups: heated humidified high flow nasal cannula (hhhfnc) and nasal intermittent positive pressure ventilation (nippv). this will be a prospective unblinded randomized controlled study, designed as a non-inferiority trial. primary outcome: the primary outcome will be rate of treatment failure (need for intubation) within 7 days of starting the study treatment

Eligibility criteria:
inclusion criteria: * infants born at 24-27+6 weeks of gestation and up to 28 days of life who are extubated for the first time after birth or immediately after surfactant administration via (intubation-surfactant-extubation) insure or (minimally invasive surfactant therapy) mist procedures. * infants born at 28-36+6 weeks of gestation and up to 28 days of life who are candidates for non-invasive support either as a primary modality after birth or post extubation. * signed parental informed consent by one of the parents exclusion criteria: * infants who are unlikely to survive the immediate postnatal period or who have significant congenital abnormalities * presence of a pneumothorax prior to enrollment * hemodynamic instability due to sepsis or hemorrhage * inability to obtain parental consent * shortage of suitable equipment * infants who were intubated solely for surgery
preventive effect of left bundle branch area pacing versus right ventricular pacing on all cause death, heart failure progression, and ventricular dyssynchrony in patients with substantial ventricular pacing (protect-sync): multicenter prospective randomized controlled trial

Conditions: Bradyarrhythmia; Atrioventricular Block; Left Bundle Branch Area Pacing

Summary: protect-sync study is a multicenter, randomized, controlled trial. a total of 7 medical centers across republic of korea will enroll 450 patients during 2 years of enrollment period, and followed for 2 years of follow-up period. the purpose of this study to compare the clinical outcomes of left bundle branch area pacing (lbbap) compared to right ventricular pacing (rvp) in bradyarrhythmia patients who require high burden of ventricular pacing (\>40%).

protect-sync study is a multicenter, randomized, controlled trial that is designed to assess whether lbbap may reduce the risk of composite primary endpoint including all cause mortalty, hf hospitalization and/or urgent hf related visit, occurrence of pacing induced cmp, and crt-upgrade event, compared to rvp in patients who require substantial (\>40%) ventricular pacing. patients who require pacemaker and substantial (\>40%) ventricular pacing will be randomized to lbbap or rvp group, and a total of 7 medical centers across republic of korea will enroll 450 patients during 2 years of enrollment period, and followed for 2 years of follow-up period.

Eligibility criteria:
inclusion criteria: 1. at least 19 years old and willing and capable to give informed consent 2. patients who is willing and able to comply with the prescribed follow-up tests and schedule of evaluations. 3 scheduled to receive a pacemaker implant 4. substantial percentage of v pacing rate (\>40%) is anticipated exclusion criteria: 1. incapacitated or unable to read or write 2. patient who is an indication of icd or crt 3. history of prosthetic valve surgery on tricuspid valve 4. prior myocardial infarction including ventricular septum 5. life expectancy \< 12 months due to any condition 6. unavailable for at least 24 months of follow-up visits 7. pregnant or breastfeeding at the time of signing consent 8. prior heart transplant surgery 9. persistent left superior vena cava (plsvc)

Keywords: left bundle branch area pacing right ventricular pacing heart failure atrioventricular block